

Boon Cher Goh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4362334/publications.pdf>

Version: 2024-02-01

78
papers

3,991
citations

117625

34
h-index

133252

59
g-index

79
all docs

79
docs citations

79
times ranked

6125
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1531-1543.	4.2	11
2	Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer. <i>Cancer Letters</i> , 2022, 524, 91-102.	7.2	38
3	Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2583-2596.	4.2	4
4	A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210875.	3.2	4
5	Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. <i>PLoS ONE</i> , 2022, 17, e0267389.	2.5	7
6	Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1124-1131.	1.0	8
7	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	9.4	148
8	PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 1875-1881.	7.0	40
9	Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1484-1497.	5.4	55
10	The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1291-1336.	10.5	68
11	Putting the BRK on breast cancer: From molecular target to therapeutics. <i>Theranostics</i> , 2021, 11, 1115-1128.	10.0	14
12	DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. <i>Nature Communications</i> , 2021, 12, 2284.	12.8	28
13	Sustained IKK β phosphorylation and NF- κ B activation by superoxide-induced peroxynitrite-mediated nitrotyrosine modification of B56 β and PP2A inactivation. <i>Redox Biology</i> , 2021, 41, 101834.	9.0	14
14	Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 3567-3581.	2.8	3
15	A Multiplex Thyroid-Specific Assay for Quantification of Circulating Thyroid Cell-Free RNA in Plasma of Thyroid Cancer Patients. <i>Frontiers in Genetics</i> , 2021, 12, 721832.	2.3	2
16	Profiling of 3D Genome Organization in Nasopharyngeal Cancer Needle Biopsy Patient Samples by a Modified Hi-C Approach. <i>Frontiers in Genetics</i> , 2021, 12, 673530.	2.3	4
17	Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?. <i>Seminars in Cancer Biology</i> , 2021, 74, 105-120.	9.6	36
18	Epigenetic derepression converts PPAR β into a druggable target in triple-negative and endocrine-resistant breast cancers. <i>Cell Death Discovery</i> , 2021, 7, 265.	4.7	7

#	ARTICLE	IF	CITATIONS
19	Resveratrol for cancer therapy: Challenges and future perspectives. <i>Cancer Letters</i> , 2021, 515, 63-72.	7.2	164
20	Celastrol in cancer therapy: Recent developments, challenges and prospects. <i>Cancer Letters</i> , 2021, 521, 252-267.	7.2	50
21	A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. <i>BMC Cancer</i> , 2020, 20, 1118.	2.6	5
22	Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5320-5328.	7.0	14
23	Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9405.	4.1	9
24	A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1556.	12.8	12
25	Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. <i>Cancers</i> , 2020, 12, 574.	3.7	44
26	A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. <i>Pharmacological Research</i> , 2020, 156, 104686.	7.1	61
27	Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. <i>Nature Communications</i> , 2020, 11, 2086.	12.8	20
28	FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway. <i>Cancers</i> , 2019, 11, 836.	3.7	12
29	Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance. <i>Redox Biology</i> , 2019, 25, 101076.	9.0	87
30	Role of tumor-derived exosomes in cancer metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 12-19.	7.4	82
31	Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. <i>Head and Neck</i> , 2018, 40, 1425-1433.	2.0	7
32	Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. <i>Cancer Letters</i> , 2018, 417, 152-160.	7.2	69
33	Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of <i>Nigella sativa</i> Linn. <i>Pharmacological Research</i> , 2018, 129, 357-364.	7.1	54
34	A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs. <i>Pharmaceutics</i> , 2018, 10, 221.	4.5	42
35	Potential role of genipin in cancer therapy. <i>Pharmacological Research</i> , 2018, 133, 195-200.	7.1	98
36	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	61

#	ARTICLE	IF	CITATIONS
37	Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of <i>Nigella sativa</i> Linn. <i>Pharmacological Research</i> , 2018, 133, 213-214.	7.1	3
38	Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 9.	17.1	29
39	A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study. <i>Pharmaceutics</i> , 2018, 10, 123.	4.5	8
40	Clinical outcome and prognostic factors for Asian patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18748-e18748.	1.6	0
41	Wanted DEAD/H or Alive: Helicases Winding Up in Cancers. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw278.	6.3	79
42	Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2563-2570.	2.5	14
43	A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 12831-12842.	1.8	82
44	UGT1A1 Mediated Drug Interactions and its Clinical Relevance. <i>Current Drug Metabolism</i> , 2016, 17, 100-106.	1.2	20
45	Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. <i>PLoS ONE</i> , 2016, 11, e0147681.	2.5	7
46	Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. <i>PLoS ONE</i> , 2016, 11, e0164319.	2.5	9
47	⁶⁸ Ga- ϵ DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma. <i>Head and Neck</i> , 2016, 38, E76-80.	2.0	17
48	Exosome-Mediated Metastasis: From Epithelial to Mesenchymal Transition to Escape from Immunosurveillance. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 606-617.	8.7	393
49	A novel combinatorial strategy using Seliciclib [®] and Belinostat [®] for eradication of non-small cell lung cancer via apoptosis induction and BID activation. <i>Cancer Letters</i> , 2016, 381, 49-57.	7.2	41
50	Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2966-2976.	4.1	86
51	Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 283-299.	5.4	42
52	Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 575-589.	5.4	146
53	Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. <i>Cancer Science</i> , 2016, 107, 173-180.	3.9	6
54	Targeting transcription factor STAT3 for cancer prevention and therapy. , 2016, 162, 86-97.		225

#	ARTICLE	IF	CITATIONS
55	A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, e14124-e14124.	1.6	1
56	Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget, 2016, 7, 64089-64099.	1.8	16
57	High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in Singapore. Oncotarget, 2016, 7, 86730-86739.	1.8	14
58	Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with ovarian cancer. The Cochrane Library, 2015, , .	2.8	2
59	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of Oncology, 2015, 26, 998-1005.	1.2	138
60	Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. Molecular Oncology, 2015, 9, 818-833.	4.6	100
61	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1750-1760.	4.1	46
62	Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. Cancer Letters, 2015, 362, 8-14.	7.2	140
63	Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17Î²-Hydroxyexemestane and 17Î²-Hydroxyexemestane-17-O-Î²-D-Glucuronide: Application to Human Pharmacokinetics Study. PLoS ONE, 2015, 10, e0118553.	2.5	11
64	Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget, 2015, 6, 5147-5163.	1.8	79
65	Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget, 2015, 6, 29991-30005.	1.8	21
66	Manganese Superoxide Dismutase Is a Promising Target for Enhancing Chemosensitivity of Basal-Like Breast Carcinoma. Antioxidants and Redox Signaling, 2014, 20, 2326-2346.	5.4	35
67	The genomic landscape of nasopharyngeal carcinoma. Nature Genetics, 2014, 46, 866-871.	21.4	317
68	Quantification of Lâ€ergothioneine in human plasma and erythrocytes by liquid chromatographyâ€tandem mass spectrometry. Journal of Mass Spectrometry, 2013, 48, 406-412.	1.6	18
69	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PLoS ONE, 2013, 8, e54522.	2.5	46
70	A Cell-Based Small Molecule Screening Method for Identifying Inhibitors of Epithelial-Mesenchymal Transition in Carcinoma. PLoS ONE, 2012, 7, e33183.	2.5	75
71	Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatographyâ€tandem mass spectrometric method. Journal of Mass Spectrometry, 2011, 46, 202-208.	1.6	13
72	Adjuvant Chemotherapy for Nasopharyngeal Carcinoma. Medical Radiology, 2010, , 193-196.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Role of <i>UGT1A1*6</i> , <i>UGT1A1*28</i> and <i>ABCG2</i> c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. <i>Cancer Science</i> , 2007, 98, 1461-1467.	3.9	121
74	Pharmacogenetics of <i>SLCO1B1</i> gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 683-691.	1.5	87
75	Sequential External Beam Radiotherapy and High-Dose-Rate Intracavitary Brachytherapy in T1 and T2 Nasopharyngeal Carcinoma: An Evaluation of Long-Term Outcome. <i>Laryngoscope</i> , 2006, 116, 938-943.	2.0	5
76	Role of Computed Tomography Imaging in Predicting Response of Nasopharyngeal Carcinoma to Definitive Radiation Therapy. <i>Laryngoscope</i> , 2006, 116, 2162-2165.	2.0	11
77	Familial Nasopharyngeal Carcinoma in a Cohort of 200 Patients. <i>JAMA Otolaryngology</i> , 2006, 132, 82.	1.2	35
78	Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx. <i>Laryngoscope</i> , 2004, 114, 153-157.	2.0	71